Skip to main content
. 2017 Nov 3;17:101. doi: 10.1186/s12935-017-0472-0

Table 2.

DUB inhibitors for preclinical application in CSC-targeted therapy

Inhibitors Targeted DUBs CSC type References
Pimozide USP1 Osteosarcoma, glioblastoma [25, 83]
ML323 USP1
P5091 USP7, USP47 Neural, glioblastoma, multiple myeloma [57, 8587]
P22077 USP7, USP47
WP1130 USP9x, USP5, UCHL1, USP14, UCH37 Liver, breast cancer [72, 73]
IU1 USP14 Gastric, multiple myeloma [74, 75]
b-AP15 USP14, UCHL5
VLX1570 USP14
LDN-57444 UCHL1, UCHL3 Prostate [76]
TCID UCHL3, UCHL5 Multiple myeloma [84]